236 results on '"Shinefield H"'
Search Results
2. Medically recorded allergies and the risk of childhood acute lymphoblastic leukaemia
3. Efficacité du vaccin pneumococcique heptavalent conjugué (Prevenar ®) contre les infections invasives à pneumocoque : bénéfice attendu pour les enfants en France
4. Grundlagen der kinderärztlichen Betreuung
5. Automated Multiphasic Screening
6. Staphylococcus Aureus Adherence to Nasal Epithelial Cells: Studies of Some Parameters
7. Efficacité du vaccin pneumococcique heptavalent conjugué (Prevenar®) contre les infections invasives à pneumocoque : bénéfice attendu pour les enfants en France
8. Hepatitis B Vaccination Among Adolescents in 3 Large Health Maintenance Organizations
9. SAFETY OF VARICELLA VACCINE: RESULTS OF POST-MARKETING SURVEILLANCE IN 32,947 RECIPIENTS OF VARIVAX (MSD). † 987
10. SAFETY AND IMMUNOGENICITY OF HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE(Wyeth-Lederle) IN INFANCY. 986
11. Risk factors for delayed immunization among children in an HMO.
12. Safety, Immunogenicity, and Efficacy in Infancy of Oligosaccharide Conjugate Haemophilus influenzae Type b Vaccine in a United States Population: Possible Implications for Optimal Use
13. From HIV Infection to AIDS: Changes in the Microbial Ecology of Skin and Nose
14. Clinical effectiveness of seven-valent pneumococcal conjugate vaccine (Prevenar®) against invasive pneumococcal diseases: prospects for children in France
15. Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases.
16. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis.
17. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children.
18. Immunization levels among premature and low-birth-weight infants and risk factors for delayed up-to-date immunization status. Centers for Disease Control and Prevention Vaccine Safety Datalink Group.
19. MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink Project.
20. Topical sphingolipids in antisepsis and antifungal therapy.
21. Current Aspects of Infections and Diseases Related to Staphylococcus Aureus.
22. Bacterial adherence to nasal mucosal cells
23. Comparative Safety of Two Recombinant Hepatitis B Vaccines in Children: Data from the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD)
24. Variation in clinician recommendations for multiple injections during adoption of inactivated polio vaccine
25. Correlation of Human in Vivo and in Vitro Cutaneous Antimicrobial Factors
26. Bacterial Interference among Strains of Staphylococcus aureus in Man
27. Automated Multiphasic Screening
28. Role of Teichoic Acid in the Binding of Staphylococcus aureus to Nasal Epithelial Cells
29. Microbial adherence to vulvar epithelial cells
30. Assessing the cost of pneumococcal disease and the cost-effectiveness of vaccination with PNCRM7.
31. The effect of splenectomy on the mortality of mice inoculated with diplococcus pneumoniae
32. Influence of normal nasal flora andantimicrobials on resistance to injection with Staphylococcus aureus
33. Transplacental transmission of western equine encephalomyelitis
34. Influenza and the rates of hospitalization for respiratory disease among infants and young children.
35. Soziale Betreuung des benachteiligten Kindes
36. Vor- und Fürsorge in den verschiedenen Altersstufen : Pränatale und perinatale Vor- und Fürsorge
37. Vor- und Fürsorge für das Schul- und Jugendalter
38. Säuglingsfürsorge und Säuglingsschutz
39. Vor- und Fürsorge im Kleinkindesalter
40. Allgemeine Grundlagen
41. Allgemeine Biostatistik des Kindesalters
42. Anhang zu Vor- und Fürsorge für das Schul- und Jugendalter
43. Spezielle Probleme der pädiatrischen Biostatistik
44. Impfungen
45. Spezielle Prophylaxe
46. Der rheumatische Formenkreis
47. Klinische Immunologie
48. Immunologische Grundlagen
49. Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15-59 years of age.
50. The blind nasotracheal aspiration method is not a useful tool for pathogen detection of pneumonia in children.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.